Literature DB >> 8597629

Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen.

S M Kipriyanov1, F Breitling, M Little, S Dübel.   

Abstract

To increase the avidity of single-chain antibodies (scFv) for their antigen, we have fused them to core-streptavidin. The chimeric protein, expressed by the vector pSTE (plasmid for streptavidin-tagged expression) from Escherichia coli, can form tetrameric complexes, binds its antigen and contains four biotin binding sites per tetrameric complex. An additional cysteine inserted near the carboxy terminus further stabilised the complex. The scFv fusion protein tetramers could be enriched by affinity chromatography using the biotin analog 2-iminobiotin from periplasmic inclusion bodies after refolding. We have also shown that the scFv fusion protein could be used for direct detection of its antigen in ELISA when stained with biotinylated horseradish peroxidase. The affinity of the scFv-antibody complex was substantially increased by avidity effects due to the tetrameric structure. The biotin binding sites may be used for coupling other antibodies and molecules to form bispecific and bifunctional reagents.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8597629

Source DB:  PubMed          Journal:  Hum Antibodies Hybridomas        ISSN: 0956-960X


  3 in total

1.  Biotin carboxyl carrier protein co-purifies as a contaminant in core-streptavidin preparations.

Authors:  Welson Wen-Shang Wang; Dipankar Das; Mavanur R Suresh
Journal:  Mol Biotechnol       Date:  2005-09       Impact factor: 2.695

2.  Expression of recombinant antibodies.

Authors:  André Frenzel; Michael Hust; Thomas Schirrmann
Journal:  Front Immunol       Date:  2013-07-29       Impact factor: 7.561

Review 3.  Anti-SARS-CoV-1 and -2 nanobody engineering towards avidity-inspired therapeutics.

Authors:  Eugene M Obeng; Christian K O Dzuvor; Michael K Danquah
Journal:  Nano Today       Date:  2021-11-23       Impact factor: 20.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.